Oxurion NV (EBR:OXUR)
Belgium · Delayed Price · Currency is EUR 0.0030
0.00 (0.00%)
Jun 11, 2026, 12:54 PM CET
Oxurion NV Revenue
In the year 2025, Oxurion NV had annual revenue of 555.00K EUR with 18,400.00% growth. Oxurion NV had revenue of 555.00K in the half year ending December 31, 2025, with 568.67% growth.
Revenue
555.00K
Revenue Growth
+18,400.00%
P/S Ratio
0.48
Revenue / Employee
21.35K
Employees
26
Market Cap
266.07K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 555.00K | 552.00K | 18,400.00% |
| Dec 31, 2024 | 3.00K | -260.00K | -98.86% |
| Dec 31, 2023 | 263.00K | -332.00K | -55.80% |
| Dec 31, 2022 | 595.00K | -533.00K | -47.25% |
| Dec 31, 2021 | 1.13M | -950.00K | -45.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 4.11B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |